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Summary
Background: Epilepsy is refractory to medical treatment in about one-third of the
patients. The exact pathological mechanism of epilepsy pharmacoresistance is still
unclear, but a decreased antiepileptic drug (AED) uptake into the brain is suspected to
play a role. P-glycoprotein (Pgp), a transmembrane transporter encoded by ABCB1
gene and located at the endothelial cells of the blood—brain barrier (BBB), has been
associated with epilepsy pharmacoresistance.
Objective: To analyze the effect of two ABCB1 gene polymorphisms, C3435T and
G2677T/A, on phenobarbital (PB) concentrations in the cerebrospinal fluid (CSF) and
serum (S) and to assess the relationship of ABCB1 polymorphisms to phenobarbital
penetration across BBB in vivo and seizure frequency.
Methods: CSF PB and S PB concentrationsweremeasured in 60 patients with idiopathic
primary generalized epilepsy receiving phenobarbital monotherapy. CSF/S PB concen-
tration ratio was calculated as an index of phenobarbital penetration across BBB. The
patients were genotyped for the ABCB1 gene C3435T and G2677T/A polymorphisms.
Seizure frequency was recorded during the 6-month phenobarbital monotherapy.
Results: Patients with different C3435T polymorphism had significantly different
CSF PB concentrations and CSF/S PB concentration ratio. In comparison with CTAbbreviations: AED(s), antiepileptic drug(s); Pgp, P-glycoprotein; BBB, blood—brain barrier; CSF, cerebrospinal fluid; S, serum; PB,
phenobarbital.
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heterozygotes and TT homozygotes, CC homozygotes had a significantly lower CSF PB
concentration (p = 0.006) and CSF/PB concentration ratio (p < 0.001). G2677T/A
polymorphism showed no such effect (p = 0.466). CC genotype and low CSF/S PB
concentration ratio correlated with increased seizure frequency.
Conclusions: C3435T polymorphism of ABCB1 gene was demonstrated in vivo to
significantly influence the CSF/S PB concentration ratio and seizure frequency.
# 2008 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.Introduction
Epilepsy is one of the most frequent neurologic
disorders, affecting approximately 1—2% of the
world population.1,2 In around 20—30% of the
patients, the condition is refractory to medical
treatment.3—8 Clinically, epilepsy is considered
pharmacoresistant if seizures continue to occur
even though the patient is treated with two to three
first-line antiepileptic drugs (AEDs) usually used for
the treatment of given epilepsy.9—14 Characterized
by high morbidity and mortality, pharmacoresistant
forms of epilepsy remain a major health problem
despite advances in antiepileptic pharmacotherapy
and new AEDs developed in the last two dec-
ades.1,2,15
Most patients who are resistant to one major AED
are also refractory to other AEDs, although the drugs
act by different mechanisms.5,15 The real patholo-
gical mechanism of drug resistance remains obscure
in spite of numerous studies conducted.10—14
Neither the reported associations of pharmacoresis-
tance with early onset of the disease, multiple
seizure types, high frequency of seizures before
treatment, a history of febrile seizures, structural
brain lesions, and malformations of cortical devel-
opment have illuminated the mechanism of this
phenomenon.10—14,16—18 Furthermore, drug resis-
tance is not associated with the same type of epi-
lepsy. The same type of the disorder may be drug
resistant in one patient and drug responsive in
another.19 The fact that most patients with refrac-
tory epilepsy are resistant to most AEDs, although
the drugs act by different mechanisms, points to a
nonspecific mechanism such as decreased drug
uptake into the brain as a major cause of pharma-
coresistance.5,15,7,8,20,21
During the last 12 years, reports on P-glycopro-
tein 750 (Pgp) involvement in epilepsy pharmacore-
sistance have appeared in the literature.4,6—9,14,15
Pgp is a large transmembrane protein expressed in
endothelial cells of the blood—brain barrier (BBB)
and functions as a drug-transport pump transporting
a variety of drugs from the brain back into the blood
and reducing drug accumulation in the brain.22—28
Accumulated research evidence from animal and in
vitro studies suggests that some AEDs are Pgp sub-strates.9,13,15,21,29—34 Pgp is encoded by ABCB1 gene
and its expression and function are associated with
the ABCB1 C3435T polymorphism.6,8,15,35 Based on
these data, some authors report on a possible con-
nection between the C3435T polymorphism of
ABCB1 gene and pharmacoresistance in epilepsy
patients.19,36,37 On the other hand, there are studies
in which no association was found between the
C3435T polymorphism of ABCB1 gene and Pgp
expression and the pharmacoresistance of epilep-
sies.38,39
So far, there has been no conclusive evidence that
the altered Pgp function is associated with pharma-
coresistance. No in vivo human studies have been
performed to investigate if C3435T mutation of
ABCB1 gene influences the brain uptake of AEDs,
which is one of the basic presumptions of the
mechanism of pharmacoresistance.
The aim of this study was to investigate the
relationship between C3435T and G2677T/A poly-
morphisms of ABCB1 gene and the brain uptake of
phenobarbital (PB) in patients with primary general-
ized epilepsy.Methods
Genotyping was performed in 60 unrelated patients
(35 men and 25 women; mean age 37  9 years) who
suffered from idiopathic primary generalized epi-
lepsy (PGE) with tonic—clonic seizures. All patients
were diagnosed with PGE on the basis of anamnesis,
heteroanamnesis, and video-electroencephalo-
graphic recording. Symptomatic epilepsy was
excluded by magnetic resonance imaging (MRI) at
1.5 or 2 T. The patients were randomly selected
from the database of the Reference Center for
Epilepsy of the Ministry of Health and Social Welfare
of Croatia at the Zagreb University Hospital Center.
All patients received phenobarbital for 6months and
did not take any other AED or other drugs known to
be a Pgp substrate. They were also asked to keep
records on the number of seizures during the 6-
month period of phenobarbital monotherapy. After
at least 3 months of phenobarbital monotherapy,
the patients underwent lumbar puncture. Cere-
brospinal fluid (CSF) and serum (S) sampling were
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Table 1 PB concentration in CSF and S and CSF/S PB ratio with respect to C3435T genotype of 60 patients with
primary generalized epilepsy
Parameter C3435T polymorphism (mean  S.D.) p a
CC (n = 16) CT (n = 31) TT (n = 13)
PB doses/mg (range) 550.0  81.7 (400—700) 532.3  116.6 (200—800) 530.8  125.1 (300—800) 0.836
PB S (mmol/L) 102.2  15.0 102.9  25.3 103.8  13.6 0.947
PB CSF (mmol/L) 44.1  12.9 52.5  13.5 64.4  14.4 0.006
CSF/S PB 0.4  0.1 0.5  0.1 0.6  0.1 <0.001
a Kruskal—Wallis test, H = 18.52738.performed at the same time at 8.00 a.m., before the
morning dose of phenobarbital. PB concentration
was measured in both cerebrospinal fluid (CSF PB)
and serum (S PB) by fluorescence polarization immu-
noassay (FPIA) on TDx analyzers (Abbott Labora-
tories, Abbott Park, IL, USA).40 The CSF/S PB
concentration ratio was calculated as an index of
phenobarbital crossing the blood—brain barrier.
All patients were genotyped for C3435T (CC, CT,
and TT genotypes) and G2677T/A (GG, GT, and TT
genotypes) polymorphisms of ABCB1 gene. Five
milliliters of blood with Na-EDTA were collected
for genotyping procedure. Genomic DNA was
extracted from peripheral lymphocytes using salting
out procedure.41 Analysis of 2677G/T/A polymorph-
isms in exon 21 was performed according to the
method described by Cascorbi et al,42 whereas
3435C/T polymorphism in exon 26 was analyzed
by the method described by Sakaeda et al.43 Sub-
stitution G2677T/A in exon 21 was detected by
polymerase chain reaction-restriction fragment
length polymorphism (PCR-RFLP) method with NdeII
restriction endonuclease. The G and T alleles were
represented by 193 bp and 144 bp fragments,
respectively. PCR-RFLP method with BanI restriction
endonuclease was used to detect MDR1—C3435T
substitution. The C and T alleles were represented
by 198 bp and 224 bp fragments, respectively.
The study was approved by the local ethics com-
mittee and all patients gave a written informed
consent before entering the study.
Data were presented as mean values  standard
deviation (S.D.). Since the C3435T genotypes did not
follow a Gaussian distribution, Kruskal—Wallis testTable 2 PB concentration in CSF and S and CSF/S PB ratio
primary generalized epilepsy
Parameter Polymorphism (mean  S.D.
GG (n = 14) GT
PB doses/mg (range) 521.4  152.8 54
PB S (mmol/L) 104.03  11.32 10
PB CSF (mmol/L) 50.75  14.06 53
CSF/S PB 0.49  0.11 0
a Kruskal—Wallis test; H = 1.527117.was used to compare C3435T genotype groups for
phenobarbital concentration in the cerebrospinal
fluid and serum and CSF/S PB concentration ratio.
G2677T/A genotype groups were compared for the
same parameters using Kruskal—Wallis test. The
relationship between CSF/S PB concentration ratio
and seizure frequency over the 6-month period was
analyzed by ANOVA—MANOVA one-way test followed
by a Tukey test. Statistical analysis was performed
with SPSS 10.0 for Windows (SPSS Inc., Chicago, IL,
USA), and the level of significance was set at
p  0.05.Results
We found differences in both CSF PB concentration
and CSF/S PB concentration ratio among patients
with different C3435T genotypes (Table 1). The S PB
concentration did not differ among patients with
CC, CT, or TT genotype, but the penetration of
phenobarbital into the brain was reduced in CC
homozygotes, who had a significantly lower relative
concentration of phenobarbital in the cerebrospinal
fluid than did CT heterozygotes and TT homozy-
gotes.
In the same patients, no differences in CSF PB
concentration and CSF/S PB concentration ratio
were found with respect to the G2677T/A genotype
(Table 2). Not a single variant A allele was detected
in our patients, and age and sex did not correlate
with differences in CSF/S PB ratio (data not shown).
Seizure frequency correlated with CSF/S PB con-
centration ratio (Table 3). Patients with lower CSF/Swith respect to G2677T/A genotype of 60 patients with
) p a
(n = 29) TT (n = 17)
8.3  82.8 529.4  84.89 0.5353
2.7  25.73 102.36  16.96 0.8274
.38  13.45 53.69  18.87 0.4323
.53  0.11 0.52  0.14 0.466
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.PB concentration ratio had a higher incidence of
seizures during the 6-month period (ANOVA—MAN-
OVA, p = 0.001). Seizure frequency correlated with
CSF PB concentration in same manner it did with
CSF/S PB concentration ratio, while S PB concen-
tration showed no influence on seizure frequency; S
PB concentration was within therapeutic limits in all
patients.
C3435T polymorphism showed a significant cor-
relation with seizure frequency (Table 3). Patients
with CC genotype had a higher seizure frequency
than those with CT or TT genotype (ANOVA—MAN-
OVA, p < 0.001). There were more patients with CT
and TT genotypes among those with lower number
of seizures, and more patients with CC genotype
among those with higher number of seizures. In the
same patients, G2677T/A polymorphism showed no
correlation with seizure frequency (p = 0.538).Discussion
We found that both phenobarbital concentration in
the cerebrospinal fluid and CSF/S PB concentration
ratio was significantly lower in patients with the CC
genotype than in patients with CTor TT genotypes of
the ABCB1 C3435T polymorphism. The seizure fre-
quency was also higher in CC homozygotes in our
study.
A hypothesis of pharmacoresistance currently
favored by many authors is decreased drug uptake
into the brain and its restricted access to the site of
action, caused by overexpression of the multidrug
transporters, such as Pgp, at the blood—brain bar-
rier.5,7,8,14,15,20,21,30—34 As the C3435T polymorph-
ism of ABCB1 gene has been associated with the
expression and function of Pgp in humans, some
authors suggest that this polymorphism is associated
with the response to some AEDs.19,36,37 Our results
showed a correlation between C3435T polymorph-
ism, CSF/S PB concentration ratio, and frequency of
seizures, implying that Pgp may play a role in AED
pharmacoresistance.
Results of many previous studies, mainly animal
and in vitro, suggested the possible link between
Pgp and clinical response to AEDs.7,15,42,29—33 Histo-
pathologic analysis after neurosurgical operations in
epilepsy patients also suggested the same associa-
tion.4,6,8,44 However, connection between C3435T
polymorphism and AEDs uptake into the brain has
never been tested in humans in vivo. The hypothesis
is that patients with hyperexpression of Pgp at the
blood—brain barrier have reduced penetration of
AED into the brain, resulting in poor therapeutic
efficacy. Some studies have demonstrated the inter-
action of AEDs with human Pgp.45—47 Several AEDs
528 S. Basic et al.have been reported to induce Pgp or inhibit its
function,15,22—27,42 including the recent study by
Schuetz et al.48 who showed that phenobarbital
induces Pgp. However, it is still unclear if some
AEDs, including phenobarbital, could be substrates
for human Pgp. Crowe and Teoh49 tested a variety of
AEDs for their ability to be transported by Pgp
through Caco-2 monolayers and found only one,
acetazolamide, to be a weak substrate of human
Pgp. On the other hand, Pgp efflux ratios deter-
mined by in vitro high-throughput screening tests,
where the transport conditions such as pH gradient
and concentration are fixed, cannot be routinely
used to predict a possible limited brain penetration
in vivo.50 Our results show that C3435T polymorph-
ism of the ABCB1 gene, which encodes Pgp, influ-
ences the brain uptake of phenobarbital in patients
with epilepsy. Whether this finding implies that
phenobarbital is a human Pgp substrate remains
to be confirmed.
There are also studies that argue against the
influence of the ABCB1 gene C3435T polymorphism
on epilepsy pharmacoresistance.38,39 These studies
differed in inclusion criteria and involved a large
number of patients with symptomatic epilepsy
(caused by hippocampal sclerosis, cortical dyspla-
sia, stroke, or other reasons). In these patients Pgp
hyperexpression could have resulted from the
action of other local factors in the altered tissue
such as a release of excitotoxic metabolites during
frequent seizures, i.e. irrespective of the ABCB1
gene C3434T polymorphism. In addition, these stu-
dies also included patients regardless of the type of
AED therapy they received (monotherapy or poly-
therapy, substrates or non-substrates of Pgp). Thus,
inclusion of patients taking valproate could have
confounded the results, because valproate has not
been shown to be a Pgp substrate.21,51,52 Further-
more, competitive inhibition in case of AED poly-
therapy and failure to exclude patients taking other
drugs that are potential substrates or inhibitors of
PGP could also have biased the results of these
studies. To avoid these possible influences, we
included only patients with idiopathic generalized
epilepsy taking phenobarbital monotherapy.
To the best of our knowledge, the present study is
the first to show involvement of ABCB1 C3435T
polymorphism in the brain uptake of an AED in
humans in vivo. The seizure frequency was found
to correlate with CSF/S PB concentration ratio,
which fits the ‘‘decreased drug uptake’’ theory of
pharmacoresistance modulated by Pgp. On the
other hand, the sample size in our study was small
and the results should be interpreted with caution
and confirmed in a larger number of patients.
Although evidence from the literature suggests thatat least some AEDs are Pgp substrates, the exact
influence of C3435T polymorphism on different AEDs
uptake into the brain, especially in humans, remains
to be determined. More in vivo human studies
including large groups of patients could provide
better insight into the role of Pgp and ABCB1 poly-
morphism in epilepsy pharmacoresistance. Also,
attention should be paid to other factors that
may play important roles in the multifactorial phe-
nomenon of pharmacoresistance, including pharma-
codynamic and pharmacokinetic mechanisms,
polytherapy, and other protein transporters at the
blood—brain barrier.Conclusion
C3435T polymorphism of ABCB1 gene influences the
penetration of phenobarbital through the blood—
brain barrier. Correlation between C3435T poly-
morphism of ABCB1 gene, CSF/S phenobarbital
concentration ratio, and seizure frequency also
suggest involvement of ABCB1 gene in pharmacore-
sistance of idiopathic primary generalized epilep-
sies due to reduced drug uptake into the brain.
Larger in vivo human studies are needed to confirm
these results.References
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